XMD-17-51 Trifluoroacetate 是可调控蛋白激酶的嘧啶-安定酮化合物。

XMD-17-51 Trifluoroacetate is a pyrimido-diazepinone compound that regulates protein kinases.

XMD-17-51 Trifluoroacetate is a pyrimido-diazepinone compound that is able to modulate protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), polo kinase 1, 2, 3, or 4, Ack1, Ack2, Abl, DCAMKL1, ABL1, Abl mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK, ULK2, PLK, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Abl, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC. XMD-17-51 Trifluoroacetate can be used in the treatment of various diseases, disorders or conditions [1].

2436579-93-8

C23H25F3N8O3

518.49

XMD-17-51 Trifluoroacetate (1628614-50-5 free base)

DMSO:80 mg/ml (197.78 mM)
Ethanol:8 mg/ml (19.78 mM)
H2O:2 mg/ml (4.94 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years